Učitavanje...
Variant constraint by mRNA vaccines
The currently licensed mRNA vaccines for SARS-CoV-2 can elicit cross-neutralizing antibodies against B.1.351 variants of the virus, but are less potent against these variants.
Spremljeno u:
| Izdano u: | Nat Rev Immunol |
|---|---|
| Glavni autor: | |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Nature Publishing Group UK
2021
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8034506/ https://ncbi.nlm.nih.gov/pubmed/33837367 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41577-021-00548-5 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|